Intelligent Bio Solutions

INBS

Market cap $7.15M

Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026

Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS's fingerprint drug testing technology Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS's fingerprint drug testing technology

First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal second quarter and six months ended December 31, 2025, and provided a business update.

Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025.  The Company expects to report strong revenue growth across all product categories for the three- and six-month periods ended December 31, 2025.

Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market  Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its clinical study program to support its new FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. As part of its clinical study program, the Company has again partnered with Cliantha Research, a leading clinical research organization, leveraging its extensive regulatory and clinical trial expertise.

NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or pre-funded warrant) and associated Series K-1warrants and Series K-2 warrants, for expected gross proceeds to INBS of approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The Series K-1warrants and Series K-2 warrants will have an exercise price of $4.10 per share of common stock and will be exercisable immediately upon issuance. The Series K-1 warrants and Series K-2 warrants will each have a term of five years following the date a registration statement registering all warrant shares underlying the Series K-1 warrants and Series K-2 warrants is declared effective by the United States Securities and Exchange Commission (the “SEC”).

Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or pre-funded warrant) and associated Series K-1warrants and Series K-2 warrants, for expected gross proceeds to INBS of approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The Series K-1 warrants and Series K-2 warrants will have an exercise price of $4.10 per share of common stock and will be exercisable immediately upon issuance. The Series K-1 warrants and Series K-2 warrants will each have a term of five years following the date a registration statement registering all warrant shares underlying the Series K-1 warrants and Series K-2 warrants is declared effective by the United States Securities and Exchange Commission (the “SEC”).

Intelligent Bio Solutions Inc. (NASDAQ: INBS) stock is trading higher on Wednesday, with a session volume of 48.13 million compared to the average volume of 34.79 thousand, as per data from Benzinga Pro.

Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS' global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entry Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS' global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entry